Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis.
BACKGROUND
The main objective was to determine risk factors for presence of multidrug resistant bacteria (MDR) in postoperative peritonitis (PP) and optimal empirical antibiotic therapy (EA) among options proposed by Infectious Disease Society of America and the Surgical Infection Society guidelines.


METHODS
One hundred patients hospitalised in the intensive care unit (ICU) for PP were reviewed. Clinical and microbiologic data, EA and its adequacy were analysed. The in vitro activities of 9 antibiotics in relation to the cultured bacteria were assessed to propose the most adequate EA among 17 regimens in the largest number of cases.


RESULTS
A total of 269 bacteria was cultured in 100 patients including 41 episodes with MDR. According to logistic regression analysis, the use of broad-spectrum antibiotic between initial intervention and reoperation was the only significant risk factor for emergence of MDR bacteria (odds ratio (OR) = 5.1; 95% confidence interval (CI) = 1.7 - 15; P = 0.0031). Antibiotics providing the best activity rate were imipenem/cilastatin (68%) and piperacillin/tazobactam (53%). The best adequacy for EA was obtained by combinations of imipenem/cilastatin or piperacillin/tazobactam, amikacin and a glycopeptide, with values reaching 99% and 94%, respectively. Imipenem/cilastin was the only single-drug regimen providing an adequacy superior to 80% in the absence of broad spectrum antibiotic between initial surgery and reoperation.


CONCLUSIONS
Interval antibiotic therapy is associated with the presence of MDR bacteria. Not all regimens proposed by Infectious Disease Society of America and the Surgical Infection Society guidelines for PP can provide an acceptable rate of adequacy. Monotherapy with imipenem/cilastin is suitable for EA only in absence of this risk factor for MDR. For other patients, only antibiotic combinations may achieve high adequacy rates.
Augustin
Pascal
P
Department of Anesthesiology and Surgical Intensive Care Unit, Hôpital Bichat-Claude Bernard, Université Paris VII Denis Diderot, Assistance Publique Hôpitaux de Paris, 46 rue Henri Huchard, 75877 Paris Cedex 18, France. pascalaugustin@hotmail.com
Kermarrec
Nathalie
N
Muller-Serieys
Claudette
C
Lasocki
Sigismond
S
Chosidow
Denis
D
Marmuse
Jean-Pierre
JP
Valin
Nadia
N
Desmonts
Jean-Marie
JM
Montravers
Philippe
P
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy*; D011183:Postoperative Complications / Q000188:drug therapy*; D012307:Risk Factors
D000900:Anti-Bacterial Agents